fashion -WSS

fashion

author：hotspot 2025-08-26 23:44:10 - browse：36272

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Attacks on the drug industry will lead to fewer breakthroughs

hotspot

WSS

New documents shed light on MD Anderson Cancer Institute feud

Influencer to be charged after chaos erupts in New York City's Union Square

Obesity drugs seen as possible treatment for liver disease MASH

Dario to buy mental health app maker Twill in cash and stock deal

Antivenom research: Lessons from HIV applied in search for universal antidote

'Ancient DNA,' 23andMe reveal African American ancestries

hotspot

fashion

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Alkermes shareholders re

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

State Dept. review finds Biden bears some blame for Afghanistan failures

New documents shed light on MD Anderson Cancer Institute feud

Tori Bowie and the unacceptable rates of Black maternal death

Ed Silverman on new gene therapies, biosimilars, coffee, and more

As demand for Covid shots wanes, Moderna seeks its next success

TytoCare raises $49 million to build out AI

leisure time

With competition flaring, obesity drug hits goal in liver disease study

ProMED, early warning system on disease outbreaks, in peril

He's a Nobel laureate. Critics say he was misleading on Covid

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Attacks on the drug industry will lead to fewer breakthroughs

Antivenom research: Lessons from HIV applied in search for universal antidote

Wikipedia

hotspot

leisure time

explore